Table 1.
Brain region | Infusion time (min) | Groups | Amino acids |
CMRAc(ox) (µmol/g/min) |
Vcyc/VTCA(N) |
|||||
---|---|---|---|---|---|---|---|---|---|---|
GluC4 | GABAC2 | GlnC4 | AspC3 | GluC3 | Glu’ergic | GABAergic | ||||
Cortex | 15 | WT | 3.8 ± 0.2 | 3.2 ± 0.7 | 10.4 ± 0.8 | 2.3 ± 0.2 | 0.9 ± 0.2 | 0.051 ± 0.005 | – | – |
AβPP-PS1 | 3.9 ± 0.1 | 3.4 ± 0.9 | 11.9 ± 1.4 | 2.4 ± 0.5 | 0.9 ± 0.2 | 0.064 ± 0.007* | – | – | ||
90 | WT | 8.3 ± 0.8 | 7.4 ± 1.0 | 17.0 ± 1.2 | 6.9 ± 0.6 | 7.6 ± 2.4 | – | 0.43 ± 0.14 | 0.51 ± 0.14 | |
AβPP-PS1 | 9.3 ± 2.2 | 7.7 ± 1.8 | 19.0 ± 3.0 | 7.4 ± 2.8 | 6.5 ± 3.7 | – | 0.44 ± 0.06 | 0.60 ± 0.08 | ||
Hippocampus | 15 | WT | 3.9 ± 0.3 | 2.4 ± 0.4 | 12.5 ± 1.0 | ND | ND | 0.051 ± 0.003 | – | – |
AβPP-PS1 | 3.7 ± 0.4 | 2.2 ± 0.8 | 13.2 ± 0.5 | ND | ND | 0.056 ± 0.004* | – | – | ||
90 | WT | 7.3 ± 1.6 | 6.8 ± 1.7 | 16.3 ± 2.1 | ND | ND | – | 0.39 ± 0.14 | 0.50 ± 0.11 | |
AβPP-PS1 | 7.6 ± 0.9 | 6.8 ± 0.7 | 17.7 ± 0.9 | ND | ND | – | 0.48 ± 0.13 | 0.64 ± 0.16 | ||
Striatum | 15 | WT | 4.2 ± 0.1 | 2.2 ± 0.1 | 12.2 ± 1.3 | ND | ND | 0.051 ± 0.007 | – | – |
AβPP-PS1 | 3.5 ± 0.7 | 1.5 ± 0.4 | 10.7 ± 1.6 | ND | ND | 0.051 ± 0.003 | – | – | ||
90 | WT | 7.5 ± 1.7 | 6.2 ± 1.6 | 15.5 ± 3.2 | ND | ND | – | 0.38 ± 0.04 | 0.46 ± 0.12 | |
AβPP-PS1 | 8.7 ± 2.0 | 7.3 ± 2.1 | 18.6 ± 3.3 | ND | ND | – | 0.44 ± 0.06 | 0.49 ± 0.08 |
ND: not determined.
Mice were administered [2-13C]acetate for 15 and 90 min. The 13C labeling of amino acids was measured in brain tissue extracts using 1H-[13C]-NMR spectroscopy. CMRAc(ox) and Vcyc/VTCA(N) were calculated using equations (1) to (3). Values represent mean ± SEM. *p< 0.05 when compared with respective controls.